RAPT Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDRAPT Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 83% provides fundamental context to the price action. However, with RSI at 79, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $57.80 | +0.31% | ABOVE |
| 50 SMA | $47.64 | +21.70% | ABOVE |
| 100 SMA | $39.07 | +48.41% | ABOVE |
| 150 SMA | $31.20 | +85.84% | ABOVE |
| 200 SMA | $25.59 | +126.60% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RAPT in an uptrend right now?
RAPT has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, RAPT is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is RAPT overbought or oversold?
RAPT's RSI (14) is 79. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is RAPT outperforming the market?
RAPT has a Relative Strength (RS) Rating of 98 out of 99. Yes, RAPT is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is RAPT in its 52-week range?
RAPT is trading at $57.98, which is 100% of its 52-week high ($57.99) and 100% above its 52-week low ($5.67).
How volatile is RAPT?
RAPT has a Beta of 0.78 and 52-week volatility of 120%. It's less volatile than the S&P 500 - generally more stable.